Maravai Lifesciences Holdings Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 54.9% | 47.4% | 59.7% | 52.1% | 56.5% | 66.4% | 83.5% | 83.6% | 86.4% | 75.5% | 48.8% | 59.9% | 65.4% | |
| 45.1% | 52.6% | 40.3% | 47.9% | 43.5% | 33.6% | 16.5% | 16.4% | 13.6% | 24.5% | 51.2% | 40.1% | 34.6% | |
| 6.5% | 6.2% | 7.8% | 7.2% | 6.7% | 8.1% | 10.4% | 10.3% | 23.5% | 7.6% | 5.9% | 7.2% | 10.1% | |
| 58.1% | 51.9% | 63.7% | 55.3% | 59.9% | 73.1% | 84.4% | 81.4% | 85.0% | 63.3% | 44.2% | 62.3% | 61.4% | |
| 68.2% | 62.3% | 69.7% | 60.8% | 302.9% | 101.2% | 121.4% | 156.2% | -263.7% | 38.1% | 47.4% | 69.5% | -11.4% | |
| -23.1% | -9.6% | -29.4% | -13.0% | -259.4% | -67.6% | -104.9% | -139.8% | 277.3% | -13.5% | 3.8% | -29.3% | 46.0% | |
| 17.4% | 20.8% | 16.9% | 16.3% | 20.9% | 20.0% | 14.5% | 14.4% | 16.4% | 13.1% | 8.7% | 9.3% | 11.5% | |
| -30.8% | 885.1% | -34.9% | -23.1% | -269.4% | -82.4% | -112.5% | -156.4% | -108.5% | -126.4% | -9.9% | -42.4% | -65.4% | |
| -8.2% | 1,033.4% | 0.4% | -3.3% | 0.5% | 0.0% | 0.3% | -9.0% | -0.2% | 0.0% | -0.2% | -0.3% | -0.2% | |
| -9.7% | -142.9% | -18.8% | -10.3% | -151.9% | -46.4% | -63.9% | -83.5% | -61.4% | -71.6% | -5.7% | -24.1% | -37.1% | |
| 6.2% | 923.3% | 3.4% | 13.0% | -226.9% | -36.7% | -66.2% | -109.6% | -54.0% | -83.7% | 18.5% | -7.0% | -26.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.